Compare FLNT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNT | BMEA |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 91.1M |
| IPO Year | 2009 | 2021 |
| Metric | FLNT | BMEA |
|---|---|---|
| Price | $3.35 | $1.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $3.50 | ★ $9.83 |
| AVG Volume (30 Days) | 23.9K | ★ 843.8K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.67 | ★ 69.19 |
| EPS | N/A | N/A |
| Revenue | ★ $208,764,000.00 | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $0.87 |
| 52 Week High | $4.15 | $2.99 |
| Indicator | FLNT | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 46.75 |
| Support Level | $3.39 | $1.23 |
| Resistance Level | $3.52 | $1.46 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 11.84 | 34.09 |
Fluent Inc is a commerce media solutions provider that connects brands with engaged consumers by leveraging diverse advertising inventory, robust first-party data, and proprietary machine learning. The company mainly delivers customer acquisition services through scalable digital marketing campaigns, linking advertisers with targeted audiences. It reaches consumers through its Commerce Media Solutions, which integrate targeted advertising into e-commerce and digital media transaction flows on partner websites and mobile applications, as well as through its owned and operated digital media properties. The company operates in the United States, which generates the majority of its revenue, along with international markets.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.